Fecal Pancreatic Elastase Testing MarketThe global fecal pancreatic elastase testing market is projected to experience significant growth, with an expected increase from USD 15,306.7 million in 2023 ...
IMM-1-104 combined with mGnP shows promising efficacy and tolerability in first-line pancreatic cancer, with a 43% ORR and 86% DCR among seven patients. IMM-1-104 demonstrated target lesion shrinkage ...